Perfuze today said it received CE mark approval for its clot aspiration catheter Millipede 088.
The Ireland-based company also announced that the first five acute ischemic stroke patients have been treated with the device.
“Our initial experience with the device has been very positive, I believe the large bore and distal flow control capability offers unique safety and efficacy advantages over existing devices,” John Thornton, an interventional neuroradiologist at Beaumonth Hospital, who performed the first case, said in a news release.
Millipede 088 has a 0.088 in. inner diameter with a distal tip surface area increase of up to 50% over existing devices with an equivalent increase in aspiration power and distal flow control that could prevent distal emboli, according to the company.
“Our super bore aspiration technology has the potential to increase the rate of first-pass TICI 3 thrombectomies while saving time, both of which may translate into better clinical outcomes for stroke patients,” CEO Wayne Allen said.
“I am extremely pleased with the device. In the thrombectomy case that I performed, the Millipede 088 was used as primary therapy for the patient. It ingested a large occlusive M1 clot in a single pass, resulting in a mTICI 3 reperfusion (complete vessel re-opening) in less than 15 minutes,” Matt Crockett, an interventional neuroradiologist at Beaumont Hospital said.
